Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 12/20 | 0.38 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.37 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.35 |
| ▸ | TACR1 | P25103 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | KDM1A | O60341 | 1/20 | 0.34 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.34 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31386491 | 1.00 | RORC (0.38) | RORCGPR119CHRM3TACR1KDM4E | |
| SCHEMBL30759653 | 1.00 | RORC (0.38) | RORCGPR119CHRM3TACR1KDM4E | |
| SCHEMBL23042967 | 0.86 | RORC (0.39) | RORCGPR119TACR1KDM4EPKM | |
| SCHEMBL23043737 | 0.85 | GPR119 (0.37) | RORCGPR119TACR1KDM4EPKM | |
| SCHEMBL23042964 | 0.85 | GPR119 (0.37) | RORCGPR119TACR1KDM4EPKM | |
| SCHEMBL25244104 | 0.84 | ABCB1 (0.39) | RORCGPR119TACR1KDM4EPKM | |
| SCHEMBL30392103 | 0.84 | RORC (0.37) | RORCGPR119KDM4EPKMKDM1A | |
| SCHEMBL23043365 | 0.83 | GPR119 (0.35) | RORCGPR119KDM4EPKMKDM1A | |
| SCHEMBL30977200 | 0.83 | RORC (0.38) | RORCGPR119TACR1KDM4EPKM | |
| SCHEMBL30977202 | 0.83 | RORC (0.38) | RORCGPR119TACR1KDM4EPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250059205-A1 | Heterocyclic Compounds and Methods of Use | AMGEN INC. (US) | 2025-02-20 | — | — | US | disclosed |
| CN-117561063-A | Heterocyclic compounds and methods of use | 安进公司 | 2024-02-13 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250059205-A1 | Heterocyclic Compounds and Methods of Use | KRAS, NRAS, HRAS | RORC 796/4885GPR119 2070/4885CHRM3 4809/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.